Lucid Diagnostics Inc (NASDAQ:LUCD) is set to release its Q4 2024 earnings on Mar 24, 2025. The consensus estimate for Q4 ...

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a price ...

Publicly-traded Lucid Diagnostics brought in more than $15 million in a type of deal known as a registered direct offering, which lets the company raise money by selling stock directly to investors.

Shares of Lucid Diagnostics (NASDAQ:LUCD) fell over 14% premarket on Tuesday after the company launched a stock offering to raise approximately $15.3M in gross proceeds.

Lucid Diagnostics (LUCD) announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, ...

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy "This update is an important ...

Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...